{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:53:10Z","timestamp":1789602790959,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016132","name":"Walloon Region","doi-asserted-by":"publisher","award":["7823"],"award-info":[{"award-number":["7823"]}],"id":[{"id":"10.13039\/100016132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018985","name":"Waalse Gewest","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018985","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.esmoop.2025.105844","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:38:47Z","timestamp":1760546327000},"page":"105844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Innovative therapeutic cancer vaccine PDC\u2217lung01 with or without anti-PD-1: an open-label, dose-escalation phase I\/II study in non-small-cell lung cancer"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-2775","authenticated-orcid":false,"given":"J.","family":"Vansteenkiste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Demedts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8153-0008","authenticated-orcid":false,"given":"K.","family":"Cuppens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4478-0523","authenticated-orcid":false,"given":"E.","family":"Pons-Tostivint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0115-0030","authenticated-orcid":false,"given":"E.","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J.","family":"Borm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sibille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6673-9017","authenticated-orcid":false,"given":"B.","family":"Colinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9772-0511","authenticated-orcid":false,"given":"W.S.M.E.","family":"Theelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Biesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Van De Kerkhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Buchmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.C.","family":"Althoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Derijcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6776-8610","authenticated-orcid":false,"given":"D.","family":"Moro-Sibilot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-9128","authenticated-orcid":false,"given":"K.","family":"Laulagnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Halioua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Genin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7283-3720","authenticated-orcid":false,"given":"S.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dedry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Duchayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Collodoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Renard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Adriaenssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"De Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4387-6106","authenticated-orcid":false,"given":"F.","family":"Cantero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5005-4301","authenticated-orcid":false,"given":"J.","family":"Plumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Skrzypski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7689","key":"10.1016\/j.esmoop.2025.105844_bib1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105844_bib2","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s40265-020-01409-6","article-title":"First-line immune checkpoint inhibition for advanced non-small-cell lung cancer: state of the art and future directions","volume":"80","author":"Ackermann","year":"2020","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105844_bib3","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","article-title":"Immunotherapy in non-small cell lung cancer: facts and hopes","volume":"25","author":"Doroshow","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105844_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.coi.2013.03.003","article-title":"Manipulating the PD-1 pathway to improve immunity","volume":"25","author":"Kamphorst","year":"2013","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105844_bib5","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jtho.2019.06.010","article-title":"Clinical activity, tolerability, and long-term follow-up of durvalumab in patients with advanced NSCLC","volume":"14","author":"Antonia","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105844_bib6","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10183","key":"10.1016\/j.esmoop.2025.105844_bib7","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105844_bib8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105844_bib9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-020-01260-z","article-title":"Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) \u2013 novel approaches and future outlook","volume":"19","author":"Horvath","year":"2020","journal-title":"Mol Cancer"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105844_bib10","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105844_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/CCO.0000000000000815","article-title":"Harnessing dendritic cells for innovative therapeutic cancer vaccines","volume":"34","author":"Plumas","year":"2022","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105844_bib12","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.3390\/ijms24031897","article-title":"A new plasmacytoid dendritic cell-based vaccine in combination with anti-PD-1 expands the tumor-specific CD8+ T cells of lung cancer patients","volume":"24","author":"Hannani","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2025.105844_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.18632\/genesandcancer.229","article-title":"Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines","volume":"14","author":"Hannani","year":"2023","journal-title":"Genes Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105844_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.22.00096","article-title":"Safety, immunogenicity, and 1-year efficacy of universal cancer peptide-based vaccine in patients with refractory advanced non-small-cell lung cancer: a phase Ib\/phase IIa de-escalation study","volume":"41","author":"Adot\u00e9vi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105844_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.620374","article-title":"Dendritic cell-based immunotherapy in lung cancer","volume":"11","author":"Stevens","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105844_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1738812","article-title":"An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial","volume":"9","author":"Charles","year":"2020","journal-title":"OncoImmunology"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105844_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911397","article-title":"Plasmacytoid dendritic cells as a novel cell-based cancer immunotherapy","volume":"23","author":"Hern\u00e1ndez","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105844_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010458","article-title":"A novel cancer vaccine strategy based on HLA-A\u22170201 matched allogeneic plasmacytoid dendritic cells","volume":"5","author":"Aspord","year":"2010","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105844_bib19","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1111\/j.1600-6143.2011.03722.x","article-title":"Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases","volume":"11","author":"Aspord","year":"2011","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105844_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/vaccines9020141","article-title":"Engineering a human plasmacytoid dendritic cell-based vaccine to prime and expand multispecific viral and tumor antigen-specific T-cells","volume":"9","author":"Lenogue","year":"2021","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105844_bib21","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1097\/JTO.0000000000000334","article-title":"The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer","volume":"9","author":"Rami-Porta","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105844_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105844_bib24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105844_bib25","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.3390\/jcm12155063","article-title":"PD-1\/PD-L1 inhibitors as monotherapy in the first-line treatment of advanced non-small cell lung cancer patients with high PD-L1 expression: an expert position statement","volume":"12","author":"Isla","year":"2023","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105844_bib26","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7","article-title":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial","volume":"24","author":"\u00d6zg\u00fcro\u011flu","year":"2023","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105844_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91438","article-title":"Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients","volume":"2","author":"Gross","year":"2017","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105844_bib28","article-title":"Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum","volume":"5","author":"Ingels","year":"2024","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105844_bib29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/cancers16050981","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"16","author":"Hato","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105844_bib30","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105844_bib31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105844_bib32","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2023.07.006","article-title":"Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1","volume":"34","author":"Besse","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105844_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108516","article-title":"ARTEMIA phase 3 study: a randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors","volume":"203","author":"Liu","year":"2025","journal-title":"Lung Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:13:45Z","timestamp":1773159225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2059702925017132"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105844","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative therapeutic cancer vaccine PDC\u2217lung01 with or without anti-PD-1: an open-label, dose-escalation phase I\/II study in non-small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105844","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105844"}}